SANOFI-AVENTIS (EPA:SAN)

PRESS RELEASE

published on 12/13/2024 at 07:00, 1 year 8 months ago

Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
FDA designates tolebrutinib as Breakthrough Therapy for non-relapsing SPMS based on positive HERCULES study results. Sanofi awaits regulatory review for this innovative medicine

FDA Tolebrutinib HERCULES Study Breakthrough Therapy SPMS
BRIEF

published on 12/11/2024 at 07:05, 1 year 9 months ago

Sanofi's two combination vaccines against influenza and COVID-19 receive expedited review

COVID-19 Sanofi Flu Combined Vaccines Expedited Review
PRESS RELEASE

published on 12/11/2024 at 07:00, 1 year 9 months ago

Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US
Sanofi's two combination vaccine candidates targeting influenza and COVID-19 granted Fast Track designation in the US. Candidates combine licensed vaccines to assess safety and immunogenicity in older adults

COVID-19 Sanofi Influenza Combination Vaccine Fast Track Designation
BRIEF

published on 12/09/2024 at 20:11, 1 year 9 months ago

Sarclisa Combinations Show Promise in Multiple Myeloma Treatment

Clinical Study Multiple Myeloma Sarclisa MRD Negativity Treatment Efficacy
PRESS RELEASE

published on 12/09/2024 at 20:06, 1 year 9 months ago

Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients
New data presented at ASH demonstrates significant clinical benefit with Sarclisa-based combinations in newly diagnosed multiple myeloma patients, highlighting deep and durable responses and improved outcomes

Multiple Myeloma Sarclisa ASH MRD Negativity Clinical Benefit
BRIEF

published on 12/07/2024 at 17:35, 1 year 9 months ago

Rilzabrutinib: Promising Advances in the Treatment of IPT

Security Efficiency Phase III Rilzabrutinib TPI
PRESS RELEASE

published on 12/07/2024 at 17:30, 1 year 9 months ago

Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
Positive phase 3 study shows rilzabrutinib benefits in ITP patients. Results include platelet response, reduced bleeding, improved quality of life. Safety and efficacy highlighted

Phase 3 Study Rilzabrutinib ITP BTK Inhibitor Patient Benefit
BRIEF

published on 12/06/2024 at 07:35, 1 year 9 months ago

Sanofi Publishes Revised Financial Statements Excluding Opella

Financial Statements Biopharma Sanofi 2024 Results Opella
PRESS RELEASE

published on 12/06/2024 at 07:30, 1 year 9 months ago

Press Release: Availability of the revised financial statements for Sanofi excluding Opella
Sanofi releases revised financial statements excluding Opella. The adjustments classify Opella as discontinued operations, aligning with Sanofi's transition to a biopharma company. Q4 2024 results expected on Jan 30, 2025

Sanofi Discontinued Operations Opella Revised Financial Statements Biopharma Company
PRESS RELEASE

published on 10/25/2024 at 07:30, 1 year 10 months ago

Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance

Published on 09/11/2026 at 22:05, 49 minutes ago

Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 1 hour 29 minutes ago

Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 5 hours 54 minutes ago

Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/11/2026 at 15:25, 7 hours 29 minutes ago

Revolve Signs Agreement to Acquire 9.6 MW Operating Wind Project in the US and Secures Project-Level Debt Financing with EDC and Vancity
Published on 09/11/2026 at 15:00, 7 hours 54 minutes ago

Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update

View all ACCESSWIRE

Published on 09/11/2026 at 22:15, 39 minutes ago

Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 43 minutes ago

Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 3 hours 9 minutes ago

DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 4 hours 38 minutes ago

CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 18:07, 4 hours 47 minutes ago

Holding(s) in Company

View all EQS

Published on 09/11/2026 at 07:00, 15 hours 54 minutes ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 15 hours 54 minutes ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/10/2026 at 19:30, 1 day 3 hours ago

Availability of the 2026 Interim Financial Report
Published on 09/10/2026 at 07:00, 1 day 15 hours ago

2026 H1 results and new identity
Published on 09/09/2026 at 18:45, 2 days 4 hours ago

Successful launch of a €500 million bond issue

View all LES ECHOS COMFI WIRE

News